Total Valuation
Curative Biotechnology has a market cap or net worth of $6.68M. The enterprise value is $10.21M.
Market Cap$6.68M
Enterprise Value$10.21M
Share Statistics
Curative Biotechnology has 6,819,907 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,819,907
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Curative Biotechnology’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 31.76%.
Return on Equity (ROE)0.37
Return on Assets (ROA)-1.07
Return on Invested Capital (ROIC)31.76%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee0.00
Profits Per Employee-565.77K
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Curative Biotechnology is ―. Curative Biotechnology’s PEG ratio is 2.71.
PE Ratio―
PS Ratio0.00
PB Ratio-135.42
Price to Fair Value-135.42
Price to FCF-948.65
Price to Operating Cash Flow-7.18
PEG Ratio2.71
Income Statement
In the last 12 months, Curative Biotechnology had revenue of 0.00 and earned -2.26M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-87.84K
Operating Income-1.50M
Pretax Income-2.26M
Net Income-2.26M
EBITDA-1.41M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.03M and capital expenditures 5.00, giving a free cash flow of -1.03M billion.
Operating Cash Flow-1.03M
Free Cash Flow-1.03M
Free Cash Flow per Share-0.15
Dividends & Yields
Curative Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.62
52-Week Price Change-45.38%
50-Day Moving Average1.28
200-Day Moving Average―
Relative Strength Index (RSI)59.47
Average Volume (3m)181.23K
Important Dates
Curative Biotechnology upcoming earnings date is May 25, 2021, Before Open (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateMay 25, 2021
Ex-Dividend Date―
Financial Position
Curative Biotechnology as a current ratio of 0.01, with Debt / Equity ratio of -21.22%
Current Ratio0.01
Quick Ratio0.01
Debt to Market Cap<0.01
Net Debt to EBITDA-0.93
Interest Coverage Ratio-1.50
Taxes
In the past 12 months, Curative Biotechnology has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Curative Biotechnology EV to EBITDA ratio is -583.76, with an EV/FCF ratio of -950.16.
EV to Sales0.00
EV to EBITDA-583.76
EV to Free Cash Flow-950.16
EV to Operating Cash Flow-950.16
Balance Sheet
Curative Biotechnology has $145.26K in cash and marketable securities with $1.36M in debt, giving a net cash position of -$1.21M billion.
Cash & Marketable Securities$145.26K
Total Debt$1.36M
Net Cash-$1.21M
Net Cash Per Share-$0.18
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Curative Biotechnology is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast30.10%